血液肿瘤免疫及靶向药物治疗相关性感染预防及诊治中国专家共识(2025年版)  

Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies(2025)

作　　者：中华医学会血液学分会感染学组 中华医学会血液学分会淋巴细胞疾病学组 中国临床肿瘤学会淋巴瘤专家委员会 刘启发[2] 钱文斌 赵维莅[4] Infectiology Group,Chinese Society of Hematology,Chinese Medical Association;Lymphocytic Disease Group,Chinese Society of Hematology,Chinese Medical Association;Lymphoma Expert Committee of Chinese Society of Clinical Oncology;Liu Qifa;Qian Wenbin;Zhao Weili(不详;Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Hematology,The Second Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310009,China;Shanghai Rui Jin Hospital,Shanghai Institute of Hematology,Shanghai 200025,China)

机构地区：[1]不详 [2]南方医科大学南方医院,南方医科大学血液病研究所,广州510515 [3]浙江大学医学院附属第二医院,浙江大学血液病研究所,杭州310009 [4]上海交通大学医学院附属瑞金医院,上海血液学研究所,上海200025

出　　处：《中华血液学杂志》2025年第1期18-30,共13页Chinese Journal of Hematology

摘　　要：随着新药不断问世,免疫治疗和分子靶向药物在血液系统恶性肿瘤治疗领域显现广泛的应用前景。本版专家共识依据最新国内外循证医学证据,再次组织专家们对感染的诊断、预防及治疗推荐意见进行更新,特别纳入了近期在国内上市或即将上市的抗体和小分子靶向药物,以及针对新型冠状病毒感染的药物管理意见。同时,本指南亦参照牛津大学循证医学中心的分级标准和推荐强度,对推荐意见的格式进行了相应调整。As novel therapeutic agents continue to emerge,immunotherapy and molecular-targeted drugs demonstrate expanding application prospects in hematological malignancy treatment.This expert consensus revision incorporates the latest evidence-based medicine from domestic and international sources,updating recommendations for infection diagnosis,prevention,and treatment.The document integrates recommendations for recently launched or imminent antibodies and small molecule targeted compounds,including COVID-19 considerations.This format of recommendations is modified according to the levels of evidence of The Oxford Centre for Evidence-Based Medicine(CEBM).

关 键 词：循证医学 血液系统恶性肿瘤 分子靶向药物 推荐意见 肿瘤免疫 相关性感染 免疫治疗 靶向药物治疗 

分 类 号：R733[医药卫生—肿瘤]